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Early interventions in risk groups for schizophrenia: what are
we waiting for?
Iris E Sommer1, Carrie E Bearden2, Edwin van Dellen1, Elemi J Breetvelt1, Sasja N Duijff1, Kim Maijer1, Therese van Amelsvoort3,
Lieuwe de Haan4, Raquel E Gur5, Celso Arango6, Covadonga M Díaz-Caneja6, Christiaan H Vinkers1 and Jacob AS Vorstman1
Intervention strategies in adolescents at ultra high-risk (UHR) for psychosis are promising for reducing conversion to overt illness,
but have only limited impact on functional outcome. Recent studies suggest that cognition does not further decline during the UHR
stage. As social and cognitive impairments typically develop before the first psychotic episode and even years before the UHR
stage, prevention should also start much earlier in the groups at risk for schizophrenia and other psychiatric disorders. Early
intervention strategies could aim to improve stress resilience, optimize brain maturation, and prevent or alleviate adverse
environmental circumstances. These strategies should urgently be tested for efficacy: the prevalence of ~ 1% implies that yearly
~ 22 in every 100,000 people develop overt symptoms of this illness, despite the fact that for many of them—e.g., children with
an affected first-degree family member or carriers of specific genetic variants—increased risk was already identifiable early in life.
Our current ability to recognize several risk groups at an early age not only provides an opportunity, but also implies a clinical
imperative to act. Time is pressing to investigate preventive interventions in high-risk children to mitigate or prevent the
development of schizophrenia and related psychiatric disorders.
npj Schizophrenia (2016) 2, Article number: 16003; doi:10.1038/npjschz.2016.3; published online 9 March 2016
INTRODUCTION
Current treatment of schizophrenia starts too late
Schizophrenia is a complex brain disorder with a heterogeneous
presentation and variable outcome. Schizophrenia is relatively
common, with a prevalence ~ 1%, depending on gender, country,
and degree of urbanicity.1 A substantial proportion of patients
with schizophrenia experience marked impairments in multiple
domains necessary for daily functioning, affecting their ability
to maintain social relationships, sustain employment, and live
independently. In addition, the economic burden is substantial:
In Europe, the cost of schizophrenia-spectrum disorders, including
both direct and indirect expenses, was estimated to be almost
94 billion € in 2010.2 Remission of psychotic symptoms can
be achieved for the majority of patients,3,4 but social and
professional impairments generally persist after remission from
psychosis.5,6 The reason is that functional outcome is strongly
associated with the presence and severity of cognitive and
negative symptoms,7 indicating that positive symptoms (i.e.,
hallucinations and delusions) are not the core symptoms of the
illness. Although modest improvements in cognitive and social
functioning are achievable in adult patients,8 severe deficits in
these domains are hard to overcome. To increase therapeutic
impact, we should therefore aim to prevent the development
of severe social and cognitive impairments before they are
established.
Developmental and cognitive abnormalities early in the trajectory
of schizophrenia
Overt psychosis is not the beginning, nor the core feature of
schizophrenia, and should consequently not be the main target
for early intervention and prevention. During the past two
decades, research has focused on the period directly preceding
the first psychotic episode when subclinical psychotic features
emerge. These ultra high-risk (UHR) studies consistently observe
widespread deficits across multiple cognitive domains,9 as well as
reduced social abilities10 in youth with attenuated psychotic
symptoms. To prevent psychosis in this UHR stage, interventions
with psychotherapy and nutritional supplements11,12 have been
applied with some success. However, current data suggest that
the cognitive deficits observed at baseline in UHR individuals do
not improve with such interventions and usually remain constant
when progressing from the UHR stage to psychosis.13 in fact, most
people who meet UHR criteria already have a major psychiatric
disorder and the majority of those who do not transit to a
psychotic disorder still end up with significant psychopathology
and/or social disability.14 Indeed, most of the variance in
functional outcome is predicted by neurocognitive decrements
already present at the start of the UHR phase, regardless of
transition to overt psychosis.15,16
A logical inference from these important observations is that
strategies to prevent social-cognitive deficits should be applied
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earlier in the trajectory, i.e., during childhood and early
adolescence, or even pre- or perinatally.17 Several epidemiologic
studies demonstrate that children who developed schizophrenia
as adults have, on average, a significantly lower IQ at age 4 and 7
years,18 compared with normally developing children. These early
childhood cognitive deficits continue to progress at the onset of
adolescence, with reduced cognitive functioning at age 12 years,19
as well as significantly lower school performance at 13 and 14
years.20 Importantly, a meta-analysis on IQ during the course of
schizophrenia indicates further cognitive decline occurring before
the onset of adolescence.21 This was confirmed in a longitudinal
birth cohort with a lengthy follow-up period observing that
children, subsequently diagnosed with schizophrenia in adult-
hood, had a cognitive decline of 9 IQ points at age 13 and a
decline of 15 IQ points around the time of diagnosis as compared
with peers who did not develop the disorder.22 Recently, findings
in a large prospective longitudinal cohort of patients at increased
risk for schizophrenia due to the 22q11.2 deletion showed a
similar decrease in IQ, preceding the first psychotic episode by
7 years on average.23 Children who develop schizophrenia may
face other problems, e.g., with motor coordination and behavior.24
From these observations, we can infer that several different
neurodevelopmental pathways may lead to schizophrenia, while
similar neurodevelopmental deviations may lead to different
psychiatric disorders. Therefore, preventive interventions for
schizophrenia are likely to target different risk groups and may
decrease risk not only for schizophrenia and related psychotic
disorders, but also for a broader range of mental disorders,
including affective, personality, and substance abuse disorders.25
The goal of this paper is to discuss early interventions that may
have the potential to improve outcome by safeguarding cognitive
and social development (primary goal) or by preventing the full-
blown manifestation of psychosis (secondary goal). We will also
outline which specific subgroups within the population may be
most amenable to such strategies and, finally, what ethical and
economic aspects are relevant in relation to the use of very early
prevention strategies.
HOW TO INTERVENE: POTENTIAL STRATEGIES FOR
PREVENTION IN AT-RISK GROUPS
First, we propose strategies that can improve suboptimal
maturation of neuronal pathways during childhood. Second, we
examine interventions that can reduce environmental insults or
mitigate their impact. Third, we explore strategies that can
improve resilience, even in the presence of negative circum-
stances and/or genetic risk factors.
Improving suboptimal maturation of neuronal pathways
While abnormal dopaminergic signaling is strongly associated
with the onset of psychosis,26 gamma-aminobutyric acid (GABA)-
ergic and glutamatergic signaling defects may be critically
involved in the development of social and cognitive deficits in
schizophrenia.27–29 While GABA is an inhibitory neurotransmitter
in adult life, it is excitatory in early fetal brain development.
The chloride transporter KCC2 switches GABA from excitatory to
inhibitory. This chloride transporter can be stimulated by
activation of postsynaptic α7-nicotinic acetylcholine receptors.30
Glutamatergic compounds. To date, several strategies to alter
glutamatergic neurotransmission have been investigated for their
effect on cognition in patients with schizophrenia using glycine-
site NMDA-modulating compounds such as glycine, D-serine,
D-cycloserine, and the glycine transporter 1 (GlyT1) inhibitor
sarcosin.31 The evidence with regard to the addition of the NMDA
receptor partial agonist D-cycloserine to antipsychotic therapy
is mixed, with either exacerbation or alleviation of positive
symptoms32 and amelioration of negative symptoms.33 Efficacy
of D-serine treatment with regard to cognitive symptoms in
schizophrenia has not been convincingly demonstrated.34,35 In
addition, a recent meta-analysis demonstrated that glutamate-
positive modulators are not beneficial in the treatment of
cognitive symptoms in schizophrenia.36 Hence, studies thus far
have not shown efficacy of these glutamate-modifying com-
pounds in adult patients with schizophrenia. Yet, this approach
merits further exploration, in particular the use of such agents
during the early phases of schizophrenia. If applied early, when
abnormalities in glutamatergic transmission start to emerge in
those who develop schizophrenia, their efficacy may be increased.
Indeed, a recent preclinical study showed far-reaching normalizing
effects of D-serine on brain function in Pick1 knockout mice,
provided it was applied early. The behavioral deficits associated
with loss of function of Pick1 could be reversed, but only when D-
serine was administered neonatally, not during adult age.37 In
addition, there may be other glutamatergic-modulating agents
with potential. For instance, there is emerging evidence for a
therapeutic effect of pregnenolone in patients with schizophrenia,
a molecule with both neurosteroid and NMDA receptor-
modulating effects.38 More clinical studies are required to examine
effects and possible adverse effects of these and other glutamate-
modifying drugs, while pre-clinical studies are needed to elucidate
the mechanisms of action of these molecules on deviating
neurodevelopmental pathways and the optimal timing of such
interventions.
GABA-ergic compounds. Another potential approach to enhan-
cing cognition in those at risk for psychosis is by influencing
GABAergic pathways. Two important classes of selective GABAer-
gic drugs show promise: α5-selective inverse GABAA receptor
agonists and α2/3-selective GABAA receptor agonists.
39 The α5
subunit, which is predominantly expressed in the hippocampus, is
essential in modulating the interneuron-pyramidal network. While
the evidence for pro-cognitive effects of α5-selective inverse
agonists is equivocal in humans,40 there is potential for modula-
tion of GABAA receptors with an α5 subunit.
41,42 The results of a
first study on pro-cognitive effects in adult patients with
schizophrenia, using the α2/3-selective positive allosteric mod-
ulator MK0777, were disappointing.42 Nevertheless, the rationale
for this strategy remains appealing given the large body of
evidence for altered expression and functionality of GABAA
receptor α2/3 subunits in schizophrenia and their relevance for
cognition.39 In particular, similar to the glutamate system, it is
possible that GABAergic interventions are more effective when
applied earlier in life, when the GABA system is still building up
neural connections and therefore more amenable to change. In
addition to modifying GABAA receptor functionality, other possible
approaches to modulate the GABA system should also be studied,
including modulating GABA metabolism, using cation/chloride
transporters, neurosteroids or transcranial magnetic stimulation.43
For instance, bumetanide, which inhibits the cation/chloride
transporter NKKC1 and thereby indirectly modulates GABAergic
transmission, has been shown to change cortical circuits and
reverse sensorimotor-gating deficits.44,45 However, interference
with the GABAA receptors is not without danger, given the
increased risk for triggering epilepsy. Therefore, the development
of alternative approaches to modify GABAergic neurotransmission
with milder side-effect profiles is needed.
Choline supplementation. Perinatal supplementation with choline
is shown to improve cognitive function in animal models of
schizophrenia.46 A trial in 100 human newborns showed that
babies with perinatal supplementation more often showed
adequate inhibition at the auditory P50 paradigm than infants
without supplementation,47 indicating that a choline-enhancing
diet for pregnant women with high risk or supplementation for
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neonates may have positive effects on cholinergic function and
facilitate the development of adequate cortical inhibition.
Anti-oxidants and agents that affect the immune response. Find-
ings from murine studies suggest that both glutamatergic and
GABA-ergic transmission may be negatively affected by increased
immune activation and a negative redox balance in the brain.48 A
negative redox balance causes oxidative stress, and results from
an abundance of reactive oxygen and nitrogen species relative to
the availability of antioxidants. Both immune system and redox
abnormalities have been observed in the peripheral blood of
patients with schizophrenia, but also in those at increased
risk.49–52 The most important antioxidant for the brain is
glutathione, which plays a critical role in myelination and white
matter maturation,53 and can be replenished by nutritional
supplement of its amino acid precursor N-acetylcysteine (NAC).
NAC is non-toxic, has few side effects54 and induces an
upregulation of glutathione synthesis, which can neutralize extra
production of oxygen and nitric radicals in a stressed brain.48 NAC
also has mild anti-inflammatory effects, likely via its antioxidant
properties.54 Several rodent studies demonstrate that restoration
of the redox balance by NAC or other antioxidants during early
developmental stages can mitigate adverse effects of stress on
brain maturation,55 and rescue social or cognitive deficit
phenotypes induced by early social isolation,56 or prevent the
development of these phenotypes induced by neonatal hippo-
campal lesions.57 In addition to replenishing glutathione, NAC also
plays a role in the regulation of synaptic NMDA signaling.58 Its
positive effects on the redox balance, neuroinflammation, and
NMDA receptor functioning in combination with its mild side-
effect profile make NAC a preferred candidate molecule for further
study with preventive potential when applied early in the course
of schizophrenia.
Omega-3 type polyunsaturated fatty acids (PUFAs) also have
some antioxidative capacity59 and mild anti-inflammatory effects
on the brain.60 PUFAs are an important component of neuronal
and glial cell membranes and could facilitate synaptogenesis. Like
NAC, PUFAs have a very mild side-effect profile, and thus would be
a good candidate to study preventive effects when used early in
development. One study reported significant positive effects of
early administration of PUFAs compared with placebo in youth at
risk for psychosis on both the transition rate to full-blown
psychosis and broader functional outcome measures.61 Currently,
recruitment for a new study is ongoing to replicate this finding.62
PUFAs were shown to have some beneficial effects on neurode-
velopment and could mitigate the risk for childhood psychiatric
disorders such as autism and ADHD.63 As all neurodevelopmental
disorders form risk factors for schizophrenia,64,65 this could be an
additional route to decrease the risk for schizophrenia in at-risk
groups.
Another potential intervention to modulate the immune
response with minimal side effects is the use of probiotics. The
large impact of the microbiome on brain function is becoming
increasingly clear. Several gut bacteria are capable of producing
neurotransmitters such as GABA and acetylcholine.66 A “leaky gut”
has been hypothesized to lead to increased inflammatory
activation and have negative impact on brain maturation in
several psychiatric disorders, including schizophrenia.67 Probiotics
contain beneficial bacteria such as bifidobacterium and lactoba-
cillus that can decrease systemic proinflammatory cytokines,
increase neurotrophic factors, and reduce oxidative stress.68 In
healthy adults, these agents have been shown to reduce anxiety
and stress.69 Since probiotics have few side effects, this may be a
promising intervention for children at increased risk to develop
schizophrenia.
Reducing environmental insults or their impact
The key biological system required for stress adaptation, the
hypothalamic-pituitary-adrenal (HPA) axis, is abnormal in schizo-
phrenia and altered HPA axis functionality has been related to
both cognitive and negative symptoms in schizophrenia.70–72
Moreover, changes in the HPA axis may predate the onset of overt
psychotic symptoms since UHR patients display a blunted cortisol
stress response,73 altered basal cortisol levels,74 and abnormal
pituitary volumes.75 In addition, the appeal of interventions
aiming to reduce stress and improving resilience is based on
strong evidence linking excessive stress with biological mechan-
isms associated with schizophrenia, including central nervous
system immune activation,76 dopamine77 and glutamate76 release,
and redox balance disruption.78 In addition to interventions
directly aimed at reducing social stress, the prevention of drug
abuse during adolescence may also be a relevant strategy given
the bidirectional relation between drug abuse and stress. Not only
are the exposure to excessive stressors and alterations in the HPA
axis risk factors for drug abuse,79 the use of drugs can also be
associated with a disruption of normal stress regulation.80
Social skills training to prevent bullying and social exclusion.
Reducing bullying and peer rejection may improve social outcomes
in the general population.81 Targeted anti-bullying programs
therefore constitute a promising prevention strategy, as bullying
is frequent among youth predisposed to schizophrenia or related
disorders and often results in social isolation and chronic stress.82,83
The use of an individual coaching program for children and young
adolescents can decrease the prevalence of bullying and improve
social and cognitive functioning.84 Children who already have
some delay in cognitive, social, or motor development are at even
higher risk for being bullied and if that happens their risk for many
different psychiatric disorders increases.85 A prospective study on
41,000 adolescents showed that the incidence of psychotic
experiences decreased significantly in individuals whose exposure
to bullying ceased over the course of the study,86 indicating that
interventions that can stop bullying can impact the expression of
psychosis vulnerability. These findings underscore the relevance of
such programs in reducing stress from bullying and social isolation;
the time has come therefore to examine their preventive potential
when applied at an early age in children who are at increased risk
for schizophrenia.
Early interventions to prevent drug abuse. In addition to its
relation to stress regulation, drug abuse, especially when initiated
in the early teens, has long been recognized as an important risk
factor for schizophrenia.87 Although more studies are required for
conclusive evidence,88 results thus far indicate that interventions
for teens and their parents, which improve family communication
and rule-setting, can reduce the rate of subsequent drug abuse
and accompanying problem behavior.88,89 Given the serious
consequences of early-drug use in youth at risk for schizophrenia,
studying the efficacy of such programs in these populations is
urgent.
Improving resilience
Cognitive remediation. The main goal of cognitive remediation
(CR) is to improve neuropsychological deficits, making it an
appealing strategy to examine in the very early stages of
schizophrenia in high-risk subjects, when cognitive deficits
emerge. To date, there is increasing evidence for the benefits of
CR applied after the first psychotic episode in patients with
schizophrenia, with medium effect sizes on global cognition,
which remain measurable after at least 1 year.90 Interestingly,
these effects are larger when applied at younger age,91 after a
shorter duration of the illness,92 and in individuals with higher
cognitive levels.93 Benefits of CR applied to individuals in the UHR
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period with subclinical psychotic symptoms have been examined,
indicating both cognitive and social gains.94 CR may be more
effective when given in the period before the UHR stage when
cognition can still be saved, i.e., during childhood.
Exercise training. Physical exercise may improve performance on
different cognitive measures in patients with schizophrenia.
Interestingly, exercise is associated with changes in gene
expression related to brain plasticity,95 and improvements in both
brain structure96 and connectivity.97 Although the majority of
studies investigating the benefits of exercise have focused on the
elderly, there is some evidence for similar efficacy in youth,98
making it an excellent intervention for primary or secondary
prevention of cognitive decline and the development of severe
psychiatric disorders.
WHO TO TARGET: POTENTIAL CANDIDATES FOR
EARLY-PREVENTIVE STRATEGIES
When the focus of potential intervention is shifted from the UHR
phase to an earlier phase of development, more subjects will
be exposed to interventions, thus necessitating an even more
rigorous consideration of potential negative effects of at-risk
designation and intervention strategies. Selected populations with
high odds ratios to develop schizophrenia may provide a rational
starting point for such studies, especially since even children from
these risk groups who will not go on to develop schizophrenia
may still be affected by cognitive and social impairments.
Children with first-degree relatives with schizophrenia
Children with first-degree relatives suffering from schizophrenia-
spectrum disorder have, on average, a 10-fold increased risk
to develop the disease themselves.99 Cognition is also affected
in adult first-degree relatives—even in those who have not
themselves developed schizophrenia—albeit to a lesser degree
compared with the impairments observed in clinically
affected individuals.9 Risk for schizophrenia is not only increased
in children from schizophrenia patients, but also in children
from those with bipolar disorder.100 Interventions to prevent the
development of cognitive deficits may therefore be relevant to
those youngsters who are in fact early in the trajectory of
schizophrenia, but also for the remainder of this group who will
not develop the illness.
Children with 22q11.2 deletion syndrome
The 22q11.2 deletion syndrome (22q11DS) has an estimated
incidence of 1 in 2,000 and is the strongest single genetic risk
factor for schizophrenia currently known, with approximately 1
in 4 individuals with 22q11DS developing the illness. In these
individuals, the principal clinical characteristics cannot be
distinguished from schizophrenia in the general population.101
Notably, a substantial proportion of 22q11DS children, when
followed prospectively, display a decrease in IQ over time.102
Moreover, consistent with the observed cognitive abnormalities
predating the onset of psychosis in the general population (see
Figure 1),19,20 22q11DS children who showed an early-cognitive
decline had a threefold increased risk to be diagnosed later with a
schizophrenia-spectrum disorder, compared with those without
cognitive decline.23 The observation of increased plasma levels
of the amino acid proline in approximately one third of indivi-
duals with 22q11DS103 is notable as evidence suggests that
proline influences glutamatergic neurotransmission.104,105 Indeed,
findings of several studies indicate that high plasma proline levels
influence brain function in 22q11DS patients,106,107 suggesting
that strategies to alter glutamatergic neurotransmission may be of
particular relevance for this population. In conclusion, given their
relative high-conversion rate and well-documented cognitive
decline, children with a known 22q11 deletion are a small, but
appealing target population for early-intervention strategies.
Figure 1. Hypothesized typical course of schizophrenia. (a) shows the clinical course of the disease. (b) shows the hypothesized course of the
underlying molecular mechanisms.
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Carriers of other CNVs associated with schizophrenia
In addition to 22q11DS, other copy number variants (CNVs) are
also associated with increased risk of schizophrenia, including
microdeletions at 1q21.1, 3q29, 15q11.2, and 17q12, as well as
duplications at 15q11-13, 15q13.3, 16p11.2, and 16p13.1.108 Each
of these variants is also associated with increased rates of other
neurodevelopmental phenotypes, particularly autism spectrum
disorders, intellectual disability, and epilepsy,109 as well as
abnormal morphological features. These characteristics may cause
this risk group to be vulnerable to social stress, therefore
strategies to improve resilience and reduce social stress may be
of particular benefit. These CNVs occur at very low rates in the
population108 and even when considered together, they include
only a small proportion of all schizophrenia patients. In contrast,
the risk to develop schizophrenia in individual carriers of any one
of these CNVs is substantial, with estimated odds ratios ranging
between 2 and430,108 making the population of carriers of these
CNVs a target group for use of preventive measures early in the
developmental trajectory.
Youth experiencing transient psychotic symptoms
Psychotic experiences are common among young children,
occurring in about 15% of children aged 9–11 years old.110 In
most cases, these symptoms are transient, but approximately one
third of this group experiences psychotic symptoms for over a
year. For children with psychotic symptoms, the chance to
develop a schizophrenia-spectrum disorder by the age of 26 is
between 5 and 16 times increased, depending on the number and
severity of the psychotic experiences.111
Children with psychotic experiences are not only at increased
risk for schizophrenia, but also for other psychiatric disorders,112
and therefore general interventions to prevent deterioration may
be of added value. Based on retrospective information obtained
from adult patients with schizophrenia, 40% already experienced
one or more psychotic features in childhood.15 Thus, preventive
measures should be considered in children with psychotic
experiences, in particular when they are persistent, when more
than one feature is present, or when one severe psychotic
symptom is present.
ETHICAL AND ECONOMIC ASPECTS OF EARLY-PREVENTIVE
STRATEGIES
With the exception of the pharmacological agents, the interven-
tions discussed under 'How to intervene: potential strategies for
prevention in at-risk groups' are non-invasive and safe, thereby
fully respecting the adagium primum non nocere (i.e., first do no
harm). Furthermore, some interventions, such as exercise training
and bullying prevention programs are non-specific and likely to be
beneficial for any youth, regardless the risk of developing
schizophrenia. Nevertheless, the identification as a person at risk
may have negative impact on a person’s well-being. Furthermore,
without exception, the suggested interventions will be costly and
it is therefore a key to provide the intervention for those who
need it most.
Disclosing presence of psychotic experiences and at-risk status
When communicating information about at-risk status for severe
disorders to children and their families, a leading ethical question
is whether telling children about their at-risk status harms them.
This question should be considered in the context of the
anticipated gain of the intervention, which is the prevention or
mitigation of social and cognitive impairments and, ideally, of the
full manifestation of a major psychiatric disorder. Communicating
information about an increased risk for a major psychiatric
disorder may cause anxiety, but it may also be beneficial for both
the child and the family, as it may validate perceived social or
cognitive problems or emerging psychotic experiences. Disclosure
also provides the opportunity to educate child and family, for
instance about other potential risk environments, early-symptom
recognition, and lifestyle adjustments. More extensive discussions
of considerations regarding ethical aspects of disclosing risk status
have recently been published.113,114
Economical aspects of early-intervention strategies
Even when focusing on selected groups with high a priori risk for
schizophrenia, it is important to assess the economical feasibility
of early-intervention strategies. What are the expenses required
for the implementation of the interventions and how do they
weigh against the expected gains, i.e., the number of patients in
whom a cognitive and social decline, and full development of
schizophrenia is averted and improvement in cognitive and social
functioning in those who do not make a transition to a psychotic
disorder? In the absence of reliable data on effect sizes of the
interventions discussed in this paper, we have modeled several
scenarios to provide some insight into this question. In Figure 2,
we present three scenarios (Figure 2a–c) based on different effect
size assumptions, which are expressed as the prevention rates of
the intervention (5%, 10%, and 25% respectively). For instance, a
prevention rate of 10% implies that in 1 out of 10 individuals who
are exposed to the intervention, the onset of social and cognitive
dysfunction, and full development of schizophrenia is prevented.
The general population, with a lifetime incidence of about 1%, is
provided as a reference. The figure should be viewed while
keeping in mind a conservative estimate of the economic burden
related to one individual who develops a psychotic disorder, i.e.,
~ 167k € per 10 years (indicated with the dotted black line).115
While interventions at low costs may be cost-effective in high-risk
groups, we should also consider that there is a general willingness
to pay for preventive interventions to safeguard future genera-
tions from severe dysfunction.
It is also important to realize that all the aforementioned risk
groups have increased odds of multiple psychiatric disorders, not
just schizophrenia. Therefore, early intervention in any of these
groups may also be relevant in the prevention of a broad
spectrum of psychiatric disorders, thereby enlarging the antici-
pated gain of the intervention. Finally, the selection of a high-risk
population can be further improved when more expensive
interventions are to be examined. This could be achieved by
selecting those children who have more than one risk factor. For
example, youth with subclinical psychotic symptoms and a family
history of schizophrenia may be a strategic population to study
such interventions before any associated cognitive dysfunction
progresses to more severe levels.
DISCUSSION AND CONCLUSIONS
The past 20 years have largely increased our understanding of
the developmental trajectory of schizophrenia. We now have
some basic knowledge on environmental circumstances and
neurobiological factors that can positively or negatively affect this
developmental trajectory. Yet, this knowledge is not translated
into preventive interventions in early stages. Each decade, many
young people around the world develop schizophrenia without
even a trend towards lowering the incidence. Time is pressing
for research into early-preventive interventions to diminish the
development of schizophrenia-spectrum disorders in future
generations.
Psychosis is a core, but also a late symptom of schizophrenia,
generally starting in early adolescence during the UHR period and
progressing to the first psychotic episode in young adulthood.
However, cognitive and social dysfunctions emerge at a much
earlier stage and evolve to become the most disabling symptoms.
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Figure 2. (a–c) Economical feasibility of early-intervention strategies. This figure indicates the total cost (in €) of any intervention strategy (x
axis) to prevent the development of schizophrenia in one individual (y axis). (a–c) represent three scenarios based on different prevention
rates of the intervention (5%, 10%, and 25% respectively). For reference, the black dotted line represents the estimated economic burden of
one individual who develops a psychotic disorder calculated for a time span of 10 years. The area under the dotted line indicates an economic
benefit since the costs of the preventive strategy to prevent one transition to schizophrenia outweighs the economic burden of one affected
individual. Several factors influence whether a preventive intervention is cost-effective, including (i) the costs of the intervention (x axis). (ii)
lifetime risk for a psychotic disorder in the target population (different line colors) with lower risks resulting in a reduced cost-effectiveness.
The blue line refers to the risk for schizophrenia in the general population (1%), the red line applies to the selected population of 22q11DS
individuals with a 25% lifetime incidence of schizophrenia and (iii) the effectiveness of the intervention; that is, in what proportion of
individuals can the development of a psychotic disorder be averted as a result of the intervention?
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Compromised cognitive functioning in children who later develop
schizophrenia as compared with their peers is already present at
age 4116 and may well be impaired from the very beginning. In
addition, there is evidence for a deterioration in cognitive and
social functioning in early adolescence.21 While interventions to
relieve psychotic symptoms in the UHR period or during psychotic
episodes have only limited impact on long-term functional
outcome, preventing cognitive and social decline during child-
hood or early adolescence may have substantial impact on long-
term functioning. In this perspective, we propose that the term
premorbid may no longer be accurate when used in schizophrenia
as it erroneously suggests that the disease process starts with
either the prodromal stage or the onset of the first psychotic
symptoms.
Several interventions that are well-tolerated can potentially
prevent severe cognitive dysfunction when applied early in the
course of the disorder. Such interventions may aim to avoid
or mitigate disadvantageous circumstances, such as bullying,
social exclusion, or drug use in children at increased risk. Other
strategies include the optimization of brain maturation or
resilience with interventions to improve the redox balance or
immune status of the brain. Since abnormalities in the develop-
ment and maturation of NMDA and GABA receptors may play an
important role in the decline of cognition during childhood and
adolescence, this also provides a potential mechanistic back-
ground for preventive interventions.
Given the population rate of schizophrenia of about 1%,
unfeasibly large samples would be required to provide sufficient
power for the study of the efficacy of the interventions discussed
here. However, we can now identify a substantial number of
selected risk populations in childhood on the basis of genetic or
clinical characteristics, such as those with first-degree relatives
with schizophrenia, with known genome abnormalities, or
children experiencing one or more psychotic symptoms. These
early identifiable risk groups provide a rational starting point to
examine the efficacy of existing and promising early interventions,
with regard to the prevention of social and cognitive deficits in
schizophrenia.
Moreover, it is plausible that in the near future neuroimaging,117
electroencephalogram, or blood-based biomarkers can be used to
further improve the selection of individuals. For instance, reduced
P300 amplitude may already be present during childhood and
could thus be used to improve selection.118 Another example is
the measurement of increased inflammatory parameters (e.g.,
C-reactive protein, IL1β, IL-6, or other parameters) in children with
psychotic symptoms to prioritize those who may benefit most
from supplements such as NAC or PUFA.
Although the field generally agrees that early intervention is
one of the most important goals in schizophrenia research, only
few studies directly test efficacy of such intervention strategies.
A possible explanation for this paucity is that most risk groups
have rather low conversion rates, with only 10–25% of youngsters
developing the disorder. This may indeed be a reason for not
testing interventions with moderate to severe side effects.
However, most preventive interventions described in this manu-
script have very mild side-effect profiles, and even reach beyond
non nocere as they are beneficial even to those who will not
develop schizophrenia.
We now have a basic understanding of how to act early and
therefore it is time to proceed. Randomized clinical trials are urgently
needed to provide a scientifically sound basis for the use of early-
intervention strategies in clinical practice. Moreover, we need to
evaluate the cost-effectiveness of these interventions. The high-risk
groups discussed in this review provide an appealing and strategic
starting point. The required trials will be costly and challenging but it
is time they are initiated, given their high potential to uncover novel
possibilities for preventing or at least mitigating the course of
schizophrenia, perhaps even in the near future.
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